Polysomnographic predictors of persistent continuous positive airway pressure adherence in patients with moderate and severe obstructive sleep apnea  by Chen, Yung-Fu et al.
Kaohsiung Journal of Medical Sciences (2015) 31, 83e89Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEPolysomnographic predictors of persistent
continuous positive airway pressure adherence in
patients with moderate and severe obstructive
sleep apnea
Yung-Fu Chen a, Liang-Wen Hang b, Chun-Sen Huang b, Shinn-Jye Liang b,
Wei-Sheng Chung c,*a Department of Healthcare Administration, Central Taiwan University of Science and
Technology, Taichung, Taiwan
b Sleep Medicine Center, Department of Internal Medicine, China Medical University
Hospital, Taichung, Taiwan
c Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare,
Taichung, TaiwanReceived 7 April 2014; accepted 15 September 2014
Available online 18 December 2014KEYWORDS
Adherence;
Continuous positive
airway pressure
(CPAP);
Obstructive sleep
apnea (OSA);
Polysomnographic
parametersConflicts of interest: All authors d
* Corresponding author. Department
Min Road, Taichung Taiwan.
E-mail address: chung.w53@msa.h
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2014, KaohsiuAbstract Extensive use of continuous positive airway pressure (CPAP) has positive clinical
benefits for most patients with obstructive sleep apnea (OSA). However, patient adherence
is a major limiting factor to the effectiveness of CPAP treatment. This study determined the
potential and quantifiable factors affecting the willingness of patients with OSA to undertake
CPAP treatment by comparing the polysomnographic parameters recorded during diagnosis and
titration. Patients with moderate and severe OSA who attended diagnostic polysomnography
(PSG) and CPAP titration at the sleep center of China Medical University Hospital (CMUH) were
included in the study. A total of 312 patients were divided into persistent users and nonusers of
CPAP according to their use of in-home CPAP following titration and a 7-day CPAP trial. Multi-
variate logistic regression analyses were used to define the potential polysomnographic predic-
tors of persistent CPAP adherence, and odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated. Most patients were men older than 50 years who were overweight or obese.
Among the patients, 146 (46.8%) became persistent CPAP users. A 10% improvement of oxygen
desaturation index (ODI) and a 10% increment in deep sleep percentage increased the chance
of persistent CPAP use 1.18-fold and 1.07-fold, respectively. In addition, the improved ODI andeclare no conflicts of interest.
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nographic parameters obtained from diagnosis and during titration can facilitate the predic-
tion of persistent CPAP use.
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Obstructive sleep apnea (OSA), a prevalent sleep disorder
characterized by recurrent airway obstruction during sleep
that causes hypoxemia and sleep fragmentation, can result in
excessive daytime sleepiness [1], mood disturbance [2],
deficits in neurobehavioral performance [3], deteriorated
functional status and quality of life, increased risk of hyper-
tension and cardiovascular disease, metabolic dysfunction,
and traffic accidents [4e8]. Overweight and obesity are
common predisposing factors for OSA [9], which frequently
causes daytime sleepiness associated with impaired daytime
performance and affects approximately 3e7% ofmiddle-aged
men and 2e5% of middle-aged women [10].
Two nights of polysomnography (PSG) is the typical
length of time required to diagnose OSA and titrate
continuous positive airway pressure (CPAP) [11] because
breathing and CPAP responses during all sleep stages can
adequately be observed. The use of CPAP is well estab-
lished to effectively treat daytime manifestations of severe
OSA. Extensive CPAP use affords substantial clinical bene-
fits, such as reduced daytime sleepiness, systolic and dia-
stolic blood pressure, insulin resistance, cardiovascular
risk, oxidative stress, total cholesterol, and inflammation
[12]. Evidence suggests that using CPAP for longer than 6
hours decreases sleepiness, improves daily functioning, and
restores memory to normal levels [13].
However, poor CPAP compliance was observed in
approximately 30% of patients with OSA in Taiwan [14],
which is substantially lower than the poor CPAP compliance
identified in Western countries (60e70%) [15]. Several
studies have reported that complaints pertaining to CPAP
use, such as inconvenience, poor mask fit, discomfort, skin
irritation, mask leaks, sore eyes, dry airway, nasal com-
plications, frequent awakening, claustrophobia, and aver-
sion to CPAP treatment, might affect CPAP compliance
[16,17]. Although several psychological and clinical pa-
rameters have been used to predict CPAP adherence,
inconsistent results have been determined [17,18]. Various
clinical predictors, including female sex, increased age,
and reduced Epworth Sleepiness Scale (ESS) scores, have a
considerable correlation with increased CPAP use [19,20].
In addition, the symptomatic severity of apnea is a critical
predictor of long-term adherence [20].
Investigating the predictors of long-term CPAP adher-
ence is crucial to treating OSA and lowering comorbidity
risk. However, few identified variables can be used to
reliably predict CPAP adherence. In this study, we deter-
mined the potential factors affecting the adherence of
patients with OSA who had been advised to undergo CPAP
treatment by using PSG parameters recorded during OSA
diagnosis and CPAP titration.Methods
Patients
We retrospectively reviewed the consecutive PSG records
of patients with OSA who were treated at the sleep center
of China Medical University Hospital (CMUH), Taichung,
Taiwan between January 2007 and December 2009. The
study was approved by the CMUH Medical Research Ethics
Committee (DMR98-IRB-292). Fig. 1 shows that a total of
661 patients with OSA were assessed for eligibility in this
study. After a 7-day trial, 349 patients were excluded
because of poor compliance as a result of severe skin al-
lergies, nasal congestion, sinusitis, stomach bloating, un-
controlled or severe bullous lung disease, pathologically
low blood pressure, severe cardiac arrhythmia, uncon-
trolled coronary artery disease, stroke, seizure, or eco-
nomic problems. The remaining 312 patients diagnosed
with moderate [15/h  apnea/hypopnea index (AHI) < 30/
h] and severe OSA (AHI  30/h) according to the American
Academy of Sleep Medicine (AASM) guidelines [21] and age
21 years [22,23] who underwent complete in-laboratory
diagnostic PSG and CPAP titration were recruited for this
study. CPAP titration was performed 1 month after the PSG
diagnosis. Because the age range of pediatric patients
began at the fetal stage and terminated at 21 years of age
[22], only patients 21 years old were included in our
investigation [23].
Patients were treated with CPAP using a fixed pressure
determined by titration during a 7-day product trial at
home prior to committing to purchase a CPAP device. To
reduce bias, the CPAP devices (Type S8; Resmed, Mar-
tinsried, Germany) utilized during the titration and the
home trial were manufactured by the same company. Pa-
tients were trained to use the CPAP and fitted for a mask by
a certified sleep technician from the Taiwan Society of
Sleep Medicine.
We assumed that patients who purchased a CPAP device
were persistent users. Participants were categorized into
persistent users and nonusers according to their use of in-
home CPAP treatment. The economic status of patients
substantially affected their willingness to purchase a CPAP
device for OSA treatment; therefore, nonusers who did not
purchase a device for economic reasons were excluded
from further study. Demographic characteristics including
sex, age, body mass index (BMI, kg/m2), neck and waist
circumferences (cm), and sleepiness index measured ac-
cording to ESS scores graded on a 5-point Likert scale
[24,25] were collected for analysis. CPAP titration was
conducted by a certified sleep technician. An effective
(optimal) CPAP pressure was determined during the one-
night CPAP titration using the following procedure:
Figure 1. A flow diagram of the sampling scheme used in this study. CPAP Z continuous positive airway pressure.
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increments of 1 cmH2O in 5-minute intervals according to
obstructive respiratory-related events (apneas, hypopneas,
respiratory effort-related arousals, snoring). The titration
procedure continued until no abnormal respiratory-related
events occurred within 30 minutes [11].
PSG
Polysomnographic studies were conducted using the Sand-
mansleep sleep diagnostic system. Continuous recordings
were used to monitor the following parameters: electroen-
cephalogram, electrooculogram, electromyogram, electro-
cardiogram, respiratory effort, nasal pressure (measured
and transmitted using a nasal cannula to a pressure trans-
ducer), oxyhemoglobin saturation (measured using a pulse
oximeter), snoring duration (measured using a vibratory
sensor), body position (measured using an accelerometer),
and nasal flow (measured using a thermistor or thermo-
couple sensor to detect the temperature of air exhaled from
the nose or mouth). Sleep stages and arousals were scored
according to the criteria proposed by Rechtschaffen and
Kales [26]. The spontaneous arousal index (AI) was defined
as the number of spontaneous arousals multiplied by the
number of hours of sleep. The oxygen desaturation index
(ODI) was defined as the mean number of events per hour
during which the oxygen saturation level decreased by >3%
during sleep. An apnea was defined as a cessation of airflow
for a minimum of 10 seconds; a hypopnea was determined
by a 30% reduction in airflow for a minimum of 10 seconds
and a peripheral capillary oxyhemoglobin desaturation
(SpO2) decrease of 4% [27].
The apnea/hypopnea index (AHI) was calculated as the
total number of apneas (central, mixed, or obstructive) and
hypopneas per hour of sleep. The AI, the total number ofarousals per hour of sleep, was determined according to
respiratory effort-related episodes occurring with a mini-
mum of 10 seconds of reduced airflow that did not fulfill
apnea or hypopnea criteria and were terminated with
arousal [27]. PSG recordings were performed overnight for
a minimum of 6 hours when patients received OSA di-
agnoses and CPAP titration studies. Patients with recording
periods that were <6 hours received another examination.
Sleep efficiency was calculated as the ratio of the total
sleep time (TST) to the total time spent in bed.
Working definitions of variables
Ten percent increments of deep sleep after CPAP titration:
the difference during deep sleep (Stages III and IV called
slow-wave sleep, SWS) between CPAP titration and initial
diagnosis was measured using PSG in 10% increments.
Spontaneous AI decrease after CPAP titration: the
decrease in spontaneous AI between CPAP titration and
initial diagnosis, measured according to PSG.
Ten percent improvement in ODI after CPAP titration:
the ODI difference between CPAP titration and initial
diagnosis was measured to determine 10% improvement.
Statistical analysis
Statistical tests were performed using SPSS for Windows
version 16 (SPSS Inc., Chicago, IL, USA). Descriptive statistics
were used to describe the characteristics of the patients,
and continuous and ordinal variables were presented as the
mean standard deviation (SD). The Student t test was used
to compare the means of baseline characteristics, poly-
somnographic data, CPAP titration, and differences between
persistent users and nonusers of CPAP. Univariate logistic
regression analysis was performed to identify the potential
Table 1 Baseline demographic and clinical characteristics
of participants (N Z 312).
Characteristics No. of
patients
%
Sex Male 266 85.26
Female 46 14.74
Age (y) 21e30 12 3.85
31e40 44 14.10
41e50 85 27.24
51e60 89 28.53
>60 82 26.28
BMI (kg/m2) BMI < 18.5 2 0.64
18.5  BMI < 24 46 14.74
24  BMI < 27 90 28.85
27  BMI < 30 78 25.00
30  BMI < 35 65 20.83
BMI  35 31 9.94
Neck
circumference (cm)
35.0 26 8.33
35.1e40 139 44.55
40.11e45.0 127 40.71
45.1e50.0 18 5.77
50 2 0.64
Waist
circumference (cm)
80.0 17 5.45
80.1e90.0 51 16.35
90.1e100.0 134 42.95
100.1e110.0 64 20.51
100.0 46 14.74
ESS 5 71 22.76
6e10 99 31.73
11e15 88 28.2
16e20 44 14.1
20 10 3.21
AHI (/h) Moderate
(15.0e30.0)
82 26.28
Severe (30) 230 73.72
Persistent CPAP users Yes 146 46.79
No 166 53.21
AHI Z apnea/hypopnea index; BMI Z body mass index;
CPAP Z continuous positive airway pressure; ESS Z Epworth
Sleepiness Scale.
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CPAP persistent users. Multivariate logistic regression ana-
lyses performed using a full model and a reduced model,
including variables with p < 0.05 in the univariate analysis,
were further used to define the predictors for persistent
CPAP use. We did not include the AHI change variable in the
multivariate logistic regression model because of a strong
correlation to ODI. Odds ratios (ORs) and 95% confidence
intervals (CIs) were also calculated.
Results
Baseline demographic and clinical characteristics of
participants
Men accounted for 85.26% of the patients, and approxi-
mately 55% of the patients were older than 50 years. Most
patients were overweight (53.85%, 24  BMI  30 kg/m2) or
obese (30.77%, BMI  30 kg/m2). A total of 147 patients
(47.11%) had a neck circumference exceeding 40 cm, and
244 patients (78.2%) had a waist circumference exceeding
90 cm. Among these patients, a substantial proportion were
diagnosed with severe OSA (73.72%, AHI  30/h). The dis-
tribution of patient ESS scores ranging from 0 to 5, 6 to 10,
11 to 15, 16 to 20, and >20 were 22.76%, 31.73%, 28.2%,
14.1%, and 3.2%, respectively. During the study, 146 pa-
tients (46.79%) became persistent users (Table 1).
Comparison of baseline characteristics between
persistent users and nonusers
Table 2 indicates that persistent CPAP users had significantly
greater BMIs (BMI: 29.08  4.90 kg/m2 vs. 27.22  4.76 kg/
m2, p Z 0.017), more severe OSA (AHI: 55.02  25.44/h vs.
45.00  23.59/h, p < 0.001), greater ODI (48.83  28.92/h
vs. 36.76  23.75/h, p < 0.001), and a higher effective
pressure during CPAP treatment (7.90  2.96 cmH2O vs.
7.05  2.56 cmH2O, p Z 0.006) than the nonusers.
Comparison of polysomnographic parameters
during the first night of OSA diagnosis between
persistent users and nonusers
Persistently CPAP users had higher AHIs (55.02  25.44/h vs.
45.00  23.59/h, p < 0.01), larger AIs (46.15  23.10/h vs.
37.64  20.90/h, p < 0.01), greater ODIs (48.83  28.92/h
vs. 36.76  23.75/h, p < 0.01), longer light sleep stages
(83.00  8.64% vs. 80.39  8.88%, p < 0.01), shorter deep
sleep stages (1.03  2.54% vs. 2.05  4.67%, p < 0.05), and a
lower mean SpO2 (91.79  4.80% vs. 93.44  2.68%,
p < 0.01) and minimal SpO2 (71.95  11.36% vs.
75.61  10.56%, p < 0.01) than nonusers (Table 3).
Changes in PSG parameters occurring between OSA
diagnosis and CPAP titration in persistent users and
nonusers
Persistent users had a considerably higher decrease in AHI
(46.30  22.95 vs. 36.97  22.09), light sleep (8.92  13.06
vs. 4.17  10.63), spontaneous AI (18.86  27.97 vs.14.42  24.25), and ODI (42.88  26.40 vs. 31.15  21.77)
than nonusers. In addition, they had a higher increase in
deep sleep percentage (1.20  4.48% vs. 0.50  4.56%)
and rapid eye movement (REM) sleep percentage
(7.73  11.45% vs. 4.67  9.18%) than nonusers (Table 4).Clinical and polysomnographic predictors of
persistent CPAP users
Demographic variables and changes in polysomnographic
variables occurring between diagnosis and CPAP titration
were considered to be predictors of persistent CPAP users.
A 10% increment in deep sleep percentage and a 10%
improvement in ODI percentage increased the chance of
persistent CPAP use 1.07-fold and 1.18-fold, respectively,
after controlling for the demographic variables and poly-
somnographic parameters.
Table 2 Comparison of baseline characteristics between CPAP persistent users and nonusers.
Variable Persistent users (N Z 146) Nonusers (N Z 166) p*
Mean  SD Mean  SD
Sex, male (%) 127 (87.0) 139 (83.7) 0.421
Mean age (y) 51.49  12.96 53.67  12.53 0.132
BMI (kg/m2) 29.08  4.90 27.22  4.76 0.017
Neck circumference (cm) 40.52  3.53 39.91  3.51 0.126
Waist circumference (cm) 99.94  12.48 97.34  12.32 0.066
ESS score 10.6  5.51 9.73  5.16 0.155
AHI (/h) 55.02  25.44 45.00  23.59 <0.001
ODI (/h) 48.83  28.92 36.76  23.75 <0.001
Effective pressure of CPAP treatment (/h) 7.90  2.96 7.05  2.56 0.006
* Student t test.
AHI Z apnea/hypopnea index; BMI Z body mass index; CPAP Z continuous positive airway pressure; ESS Z Epworth Sleepiness Scale;
ODI Z oxygen desaturation index; SD Z standard deviation.
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Frequently reported reasons for nonadherence to and
discontinuation of CPAP therapy include embarrassment,
physical discomfort, psychological factors (such asTable 3 Comparison of polysomnographic parameters at
diagnosis between CPAP persistent users and nonusers.
Variable Persistent users
(N Z 146)
Nonusers
(N Z 166)
p*
Mean  SD Mean  SD
TST (min) 301.51  52.42 300.22  54.07 0.832
Sleep
efficiency (%)a
79.84  14.05 78.57  14.80 0.437
Sleep
latency (min)
11.72  13.54 15.16  21.99 0.093
No. of hypopneas,
Stage I
83.30  39.30 74.66  37.54 0.048
Stage I, % of TST 44.21  25.16 38.77  21.79 0.044
Stage II, % of TST 38.79  21.50 41.62  19.17 0.224
Stage I þ II,
% of TST
83.00  8.64 80.39  8.88 0.009
Stage III, % of TST 0.97  2.35 1.67  3.60 0.039
Stage IV, % of TST 0.06  0.42 0.38  1.82 0.029
Stage III þ IV,
% of TST
1.03  2.54 2.05  4.67 0.019
REM sleep,
% of TST
15.97  7.92 17.56  7.82 0.075
AI (/h) 46.15  23.10 37.64  20.90 0.001
AHI (/h) 55.02  25.44 45.00  23.59 <0.001
ODI (/h) 48.83  28.92 36.76  23.75 <0.001
SpO2, mean (%) 91.79  4.80 93.44  2.68 <0.001
SpO2,
minimum (%)
71.95  11.36 75.61  10.56 0.003
* Student t test.
AHI Z apnea/hypopnea index; AI Z arousal index;
CPAP Z continuous positive airway pressure; ODI Z oxygen
desaturation index; REMZ rapid eye movement; SDZ standard
deviation; SpO2 Z peripheral capillary oxyhemoglobin desatu-
ration; TST Z total sleep time.
a Sleep efficiency (%) Z (TST/total time in bed)  100.claustrophobia), and difficulty of use [13]. In previous
studies that have defined adherence to CPAP usage as using
CPAP for a minimum of 4 h/night, 29e83% of the patients
were nonadherent [13]. In this study, we investigated the
polysomnographic predictors of persistent CPAP use by
excluding patients with financial problems and poor
compliance. Men accounted for 85.26% of the recruited
patients, a percentage that is higher than the 66.7% re-
ported in a previous study [28]. The disparity between pa-
tient sex in our study and that in the previous study might
have been because we enrolled participants who presented
with moderate and severe OSA at a tertiary hospital.
Persistent users of CPAP had more severe OSA than did
nonusers (p < 0.05, Table 2), a phenomenon that was noted
in previous studies reporting that patients with severe OSA
and higher ESS scores were more likely to adhere to long-Table 4 Comparison of CPAP persistent users and non-
users regarding changes in PSG parameters between diag-
nosis and CPAP titration.
Variable Persistent users
(N Z 146)
Nonusers
(N Z 166)
p*
Light sleepa
% of TST
8.92  13.06 4.17  10.63 <0.001
Deep sleepb
% of TST
1.20  4.48 0.50  4.56 0.001
REM sleep
% of TST
7.73  11.45 4.67  9.18 0.010
Spontaneous AI 18.86  27.97 14.42  24.25 <0.001
AHI 46.30  22.95 36.97  22.09 <0.001
ODI 42.88  26.40 31.15  21.77 <0.001
Sleep
efficiency (%)
5.04  14.00 3.20  13.26 0.227
Data are presented as mean  SD.
* Student t test.
AHI Z apnea/hypopnea index; AI Z arousal index;
CPAP Z continuous positive airway pressure; ODI Z oxygen
desaturation index; PSG Z polysomnography; REM Z rapid eye
movement; SD Z standard deviation; TST Z total sleep time.
a Light sleep Z Stages I þ II.
b Deep sleep Z Stages III þ IV.
Table 5 Demographic and polysomnographic predictors of persistent CPAP users.
Univariate Multivariate
Full model Reduced model**
Variable OR (95% CI) OR (95% CI) OR (95% CI)
Sex 1.30 (0.69e2.45)
Age (y) 0.99 (0.97e1.01)
10% increment in BMI % 1.77 (1.10e2.84)* 1.19 (0.68e2.11)
Neck circumference 1.05 (0.99e1.12)
Sleepiness index (ESS score) 1.03 (0.99e1.08)
Effective pressure of CPAP during titration 1.13 (1.03e1.23)** 1.03 (0.92e1.15)
10% increment in deep sleep % after CPAP titration 1.10 (1.03e1.16)** 1.07 (1.00e1.14)* 1.07 (1.00e1.13)*
Spontaneous AI decrease after CPAP titration 1.02 (1.01e1.03)** 1.00 (0.98e1.02)
AHI change 1.02 (1.01e1.03)***
10% improvement in oxygen desaturation
index after CPAP titration
1.22 (1.11e1.35)*** 1.18 (1.00e1.41) 1.18 (1.07e1.31)**
Multivariate logistic regression analysis using a full model and a reduced model, including variables with p < 0.05 in the univariate
analysis: *p < 0.05; **p < 0.01; ***p < 0.001.
AHIZ apnea/hypopnea index; AIZ arousal index; BMIZ body mass index; CIZ confidence interval; CPAPZ continuous positive airway
pressure; ESS Z Epworth Sleepiness Scale; OR Z odds ratio.
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tive treatment pressure. Early intervention and education
about treatment benefits, expectations, and common
problems encountered when trying to sleep when using a
CPAP device can facilitate establishing an effective CPAP
treatment [30,31]. Short-term adherence can influence
long-term patterns of CPAP adherence; sleep quality
experienced during the first 3 months and even the first few
days of CPAP therapy can enable predicting long-term use
[31]. Age and one-time use of sedatives or hypnotics during
PSG have been associated with greater short-term CPAP
compliance [18].
A 10% increment in deep sleep percentage increased the
change of persistent CPAP use 1.07-fold after demographic
and polysomnographic variables were adjusted for
(p < 0.05; Table 5). In addition, compared with nonusers,
persistent users experienced less light sleep (Stages I and II)
and more deep sleep (Stages III and IV; Table 4), indicating
that improved sleep quality plays a critical role in CPAP
adherence.
Because of a strong correlation to ODI [32,33], the var-
iable AHI was removed during the multivariate logistic
regression analysis. A 10% improvement in ODI after CPAP
titration significantly predicted persistent CPAP use
(ORZ 1.18, 95% CIZ 1.07e1.31) in a multivariate reduced
model that adjusted for demographic variables and poly-
somnographic variables. Although they are the most
effective type of PSG, the Level 1 PSG examinations used in
OSA diagnosis and CPAP titration are costly, complex, and
time-consuming. However, the Level 4 PSG portable
recording device that can be used for in-home monitoring
can be feasible because persistent CPAP users tend to have
lower ODIs and better sleep quality during CPAP titration.
Diagnosing OSA at home can reduce the possibility of CPAP-
induced insomnia and is less expensive than examinations
conducted at sleep centers [31,32,34,35].
Several limitations must be considered when interpret-
ing these findings. First, this was a retrospective study. The
results might be biased because of data collection from atertiary medical center, such as the issues of sex and
prevalence. Second, we defined persistent CPAP use as
continuous use for 1 month after diagnosis. However, the
real time of CPAP use was undeterminable because the
CPAP devices were not equipped with timers. Third,
because two nights of PSG was time-consuming for patients
and resource-intensive for the sleep center, CPAP titration
was typically arranged 1 month after diagnosis, and during
this waiting period, the physical conditions of patients
might have changed. Fourth, information pertaining to
CPAP therapy follow-up was unavailable. In addition, long-
term treatment efficacy and PSG parameter variations be-
tween laboratory and in-house use could not be deter-
mined. Lastly, because patients with poor compliance were
excluded, we cannot ensure this exclusion did not affect
adherence.
In conclusion, this study indicated that CPAP adherence
was associated with longer deep sleep and improved ODI
during CPAP titration. Improving sleep quality and reducing
oxygen desaturation is critical if patients with OSA are to
become persistent CPAP users.Acknowledgments
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